Amgen's Parsabiv's Gets EU Approval While It Languishes At The FDA
The EU Commission has approved Amgen’s Mimpara/Sensipar follow-on despite the FDA having blocked its US admission with a complete response letter for the drug.
The EU Commission has approved Amgen’s Mimpara/Sensipar follow-on despite the FDA having blocked its US admission with a complete response letter for the drug.